A Pilot Study to Assess the Safety and Efficacy of Umbilical Cord Blood-Derived Mesenchymal Stromal Cells for the Treatment of Synovitis in Horses.
Abstract: Synovitis is present before and during osteoarthritis in horses and can result in performance-limiting lameness. Twenty-four horses with lameness localized to the metacarpo-/metatarsophalangeal joint or a single joint of the carpus were enrolled in this study. We evaluated the response of intra-articular injection with 10 million activated (aMSC) or non-activated (naMSC) allogeneic equine umbilical cord blood-derived mesenchymal stromal cells (MSCs). Subjective and objective lameness was assessed on Days 0, 1, 21, and 42. The treatment injection was randomly assigned and performed following the baseline assessment on Day 0. naMSC-treated horses had straight-line lameness scores that were significantly lower on Day 21 (1.0 ± 1.15) and Day 42 (1.13 ± 1.00) than on Day 0 ( = 0.0098 and = 0.0418, respectively). aMSC-treated horses had straight-line lameness scores that were significantly lower on Day 21 (0.96 ± 1.03) and Day 42 (0.79 ± 1.05) than on Day 0 ( = 0.0011 and < 0.0001, respectively). There was no significant difference between the treatment groups for any parameter at any timepoint. In conclusion, both aMSC and naMSC allogeneic MSCs resulted in significantly improved subjective lameness scores in horses when compared to baseline lameness scores.
Publication Date: 2024-11-26 PubMed ID: 39682372PubMed Central: PMC11640105DOI: 10.3390/ani14233406Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The research evaluates whether the injection of activated and non-activated mesenchymal stromal cells derived from horse umbilical cord blood can help reduce lameness caused by synovitis in horses.
Study Design and Participants
- The study was conducted on 24 horses suffering from lameness localized to the metacarpo-/metatarsophalangeal joint or a single joint of the carpus. The lameness was a result of synovitis, a condition that can lead to osteoarthritis and greatly affect the horse’s performance.
- The treatment for every horse was determined randomly and was administered after an initial assessment on Day 0.
Treatments and Measurements
- The researchers used two types of mesenchymal stromal cells (MSCs), one type was activated (aMSC), and the other type was non-activated (naMSC).
- 10 million of these cells were injected intra-articularly (inside the affected joint) into the horses.
- The efficacy of the treatment was evaluated based on the changes in the horses’ lameness. Objective and subjective lameness assessments were carried out on Days 0, 1, 21, and 42 from the start of the treatment.
Treatment Results
- The naMSC treatment resulted in significantly lower lameness scores on Day 21 and Day 42, as compared to Day 0.
- The aMSC treatment also caused a significant decrease in lameness scores on Day 21 and Day 42 from Day 0.
- There was no significant difference observed between the effects of the aMSC treatment and the naMSC treatment at any given point in time.
Conclusions
- The study concluded that both activated and non-activated allogeneic MSCs decreased the lameness scores in horses, indicating an improvement in their condition.
- The results suggest the safety and efficacy of these cells in treating synovitis in horses, presenting a potential treatment option for dealing with this condition.
Cite This Article
APA
Seabaugh K, Rao S, Koenig JB, Pezzanite L, Dow S, Koch TG, Russell KA, Mehrpouyan S, Alizadeh AH, Goodrich LR.
(2024).
A Pilot Study to Assess the Safety and Efficacy of Umbilical Cord Blood-Derived Mesenchymal Stromal Cells for the Treatment of Synovitis in Horses.
Animals (Basel), 14(23), 3406.
https://doi.org/10.3390/ani14233406 Publication
Researcher Affiliations
- Orthopaedic Research Center, Translational Medicine Institute, Colorado State University, Fort Collins, CO 80523, USA.
- Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.
- Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, ON N1G2W1, Canada.
- Orthopaedic Research Center, Translational Medicine Institute, Colorado State University, Fort Collins, CO 80523, USA.
- Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.
- Orthopaedic Research Center, Translational Medicine Institute, Colorado State University, Fort Collins, CO 80523, USA.
- Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.
- eQcell Inc., University of Guelph, 50 Stone Road East, Guelph, ON N1G 2W1, Canada.
- eQcell Inc., University of Guelph, 50 Stone Road East, Guelph, ON N1G 2W1, Canada.
- eQcell Inc., University of Guelph, 50 Stone Road East, Guelph, ON N1G 2W1, Canada.
- eQcell Inc., University of Guelph, 50 Stone Road East, Guelph, ON N1G 2W1, Canada.
- Orthopaedic Research Center, Translational Medicine Institute, Colorado State University, Fort Collins, CO 80523, USA.
Grant Funding
- na / eQcell, Inc
Conflict of Interest Statement
Koch is the Founder and CEO of eQcell and a member of eQcell’s Board of Directors and Scientific Advisory Board. Russell, Mehrpouyan, and Alizadeh are eQcell employees. Goodrich, Dow, and Koenig are members of the Scientific Advisory Board for eQcell, Inc., and Goodrich is a Shareholder in eQcell, Inc. The remaining authors declare no conflicts of interest. The funders of this project, eQcell, Inc., did play a role in the design of this study, in that they chose the two treatments and provided the treatments free of charge. eQcell had no role in the collection, analysis, or interpretation of data or the decision to publish the results.
References
This article includes 21 references
- Vishwanath K, Secor EJ, Watkins A, Reesink HL, Bonassar LJ. Loss of Effective Lubricating Viscosity Is the Primary Mechanical Marker of Joint Inflammation in Equine Synovitis. J. Orthop. Res. 2024;42:1438–1447.
- Bertoni L, Jacquet-Guibon S, Branly T, Desancé M, Legendre F, Melin M, Rivory P, Hartmann DJ, Schmutz A, Denoix JM. Evaluation of Allogeneic Bone-Marrow-Derived and Umbilical Cord Blood-Derived Mesenchymal Stem Cells to Prevent the Development of Osteoarthritis in An Equine Model. Int. J. Mol. Sci. 2021;22:2499.
- Colbath AC, Dow SW, McIlwraith CW, Goodrich LR. Mesenchymal Stem Cells for Treatment of Musculoskeletal Disease in Horses: Relative Merits of Allogeneic Versus Autologous Stem Cells. Equine Vet. J. 2020;52:654–663.
- Pezzanite LM, Chow L, Johnson V, Griffenhagen GM, Goodrich L, Dow S. Toll-Like Receptor Activation of Equine Mesenchymal Stromal Cells to Enhance Antibacterial Activity and Immunomodulatory Cytokine Secretion. Vet. Surg. 2021;50:858–871.
- Pezzanite LM, Chow L, Phillips J, Griffenhagen GM, Moore AR, Schaer TP, Engiles JB, Werpy N, Gilbertie J, Schnabel LV. TLR-Activated Mesenchymal Stromal Cell Therapy and Antibiotics to Treat Multi-Drug Resistant Staphylococcal Septic Arthritis in an Equine Model. Ann. Transl. Med. 2022;10:1157.
- Kester W. Guide for Veterinary Services and Judging of Equestrian Events. American Association of Equine Practioners; Lexington, KY, USA: 1991. Definition and classification of lameness; p. 19.
- Koch TG, Heerkens T, Thomsen PD, Betts DH. Isolation of Mesenchymal Stem Cells from Equine Umbilical Cord Blood. BMC Biotechnol. 2007;7:26.
- Bogers SH. Cell-Based Therapies for Joint Disease in Veterinary Medicine: What We Have Learned and What We Need to Know. Front. Vet. Sci. 2018;5:70.
- Frisbie D.D. Stem Cells. In: McIlwraith C.W., Frisbie D.D., Kawcak C.E., van Weeren R., editors. Joint Disease in the Horse. Elsevier Health Sciences; St. Louis, MO, USA: 2015.
- Agung M, Ochi M, Yanada S, Adachi N, Izuta Y, Yamasaki T, Toda K. Mobilization of Bone Marrow-Derived Mesenchymal Stem Cells into the Injured Tissues after Intraarticular Injection and Their Contribution to Tissue Regeneration. Knee Surg. Sports Traumatol. Arthrosc. 2006;14:1307–1314.
- Ossendorff R, Walter SG, Schildberg FA, Khoury M, Salzmann GM. Controversies in Regenerative Medicine: Should Knee Joint Osteoarthritis Be Treated with Mesenchymal Stromal Cells?. Eur. Cell Mater. 2022;43:98–111.
- Zhang X, He J, Wang W. Progress in the Use of Mesenchymal Stromal Cells for Osteoarthritis Treatment. Cytotherapy. 2021;23:459–470.
- Molnar V, Pavelic E, Vrdoljak K, Cemerin M, Klaric E, Matisic V, Bjelica R, Brlek P, Kovacic I, Tremolada C. Mesenchymal Stem Cell Mechanisms of Action and Clinical Effects in Osteoarthritis: A Narrative Review. Genes. 2022;13:949.
- Broeckx SY, Seys B, Suls M, Vandenberghe A, Marien T, Adriaensen E, Declercq J, Van Hecke L, Braun G, Hellmann K. Equine Allogeneic Chondrogenic Induced Mesenchymal Stem Cells Are an Effective Treatment for Degenerative Joint Disease in Horses. Stem Cells Dev. 2019;28:410–422.
- Punzon E, Salguero R, Totusaus X, Mesa-Sanchez C, Badiella L, Garcia-Castillo M, Pradera A. Equine Umbilical Cord Mesenchymal Stem Cells Demonstrate Safety and Efficacy in the Treatment of Canine Osteoarthritis: A Randomized Placebo-Controlled Trial. J. Am. Vet. Med. Assoc. 2022;260:1947–1955.
- Olsson DC, Teixeira BL, Jeremias TDS, Réus JC, Canto GDL, Porporatti AL, Trentin AG. Administration of Mesenchymal Stem Cells from Adipose Tissue at the Hip Joint of Dogs with Osteoarthritis: A Systematic Review. Res. Vet. Sci. 2021;135:495–503.
- Kriston-Pal E, Haracska L, Cooper P, Kiss-Toth E, Szukacsov V, Monostori E. A Regenerative Approach to Canine Osteoarthritis Using Allogeneic, Adipose-Derived Mesenchymal Stem Cells. Safety Results of a Long-Term Follow-Up. Front. Vet. Sci. 2020;7:510.
- Knott LE, Fonseca-Martinez BA, O’Connor AM, Goodrich LR, McIlwraith CW, Colbath AC. Current Use of Biologic Therapies for Musculoskeletal Disease: A Survey of Board-Certified Equine Specialists. Vet. Surg. 2022;51:557–567.
- Donnell JR, Frisbie DD, King MR, Goodrich LR, Haussler KK. Comparison of Subjective Lameness Evaluation, Force Platforms and an Inertial-Sensor System to Identify Mild Lameness in an Equine Osteoarthritis Model. Vet. J. 2015;206:136–142.
- Wu MJ, Zhao K, Fils-Aime F. Response Rates of Online Surveys in Published Research: A Meta-Analysis. Comput. Hum. Behav. Rep. 2022;7:100206.
- Adams LR, Munoz KA. Owner Survey Suggests Cats May Be Undertreated for Pain Compared to Dogs After an Elective Ovariohysterectomy or Orchiectomy. Am. J. Vet. Res. 2024;85:1–8.
Citations
This article has been cited 0 times.Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists
